Freeze dried plasma and fresh red blood cells for civilian XXXX resuscitation.

@entity1 @entity548 @entity1755 @entity341 @entity551 @entity8450 @entity130
BACKGROUND: The last decade of @entity130 care has emphasized the role of blood products in the resuscitation of @entity548 @entity1 . Damage-control resuscitation advocates decreased crystalloid use and reintroduces blood components as primary resuscitative fluids. The systematic use of blood products have been described in military settings, but reports describing the use of @entity8450 ( @entity8450 ) or red blood cells (RBCs) in civilian prehospital care are few. We describe our preliminary results after implementing RBCs and @entity8450 into our @entity341 ( @entity341 ). METHODS: We collected data on the use of @entity8450 (LyoPlas N-w (AB)) during a 12-month period from May 31, 2013, to May 30, 2014, before RBC (0Rh (D) negative) introduction in June 2014. @entity8450 and RBCs were indicated in @entity130 and medical @entity1 presenting with clinical significant @entity548 on scene. Data were obtained from @entity341 registry and @entity1 records. RESULTS: Our preliminary results show that @entity8450 was used in 16 @entity1 (88% males) during the first year. Main @entity1 categories were @entity130 (n = 5), penetrating @entity130 (n = 4), and nontrauma (n = 7). Ten @entity1 (62%) were @entity551 with systolic blood pressures less than 90 mm Hg on scene. The majority (75%) received tranexamic acid. Of 14 @entity1 admitted to the hospital, 11 received emergency surgery and 8 needed additional transfusions within the first 24 hours. No transfusion-related complications were recorded. Two of the @entity8450 @entity1 died on scene, and the remaining 14 @entity1 were alive after 30 days. Early results from the recent introduction of RBC show that RBCs were given to four @entity1 . Two @entity1 (one penetrating @entity130 and one @entity130 @entity1 ) died on scene because of exsanguination, while additional two @entity1 (one @entity130 @entity1 and one with @entity1755 ) survived to hospital discharge. CONCLUSION: Our small study indicates that introduction of @entity8450 into civilian @entity341 seems feasible and may be safe and that logistical and safety issues for the implementation of RBCs are solvable. @entity8450 ensures both coagulation factors and volume replacement, has a potentially favorable safety profile, and may be superior to other types of plasma for prehospital use. Further prospective studies are needed to clarify the role of @entity8450 (and RBCs) in civilian @entity548 resuscitation and to aid the development of standardized protocols for prehospital use of blood products. LEVEL OF EVIDENCE: Therapeutic study, level V.
